Antifibrotic effects of quercetin in primary orbital fibroblasts and orbital fat tissue cultures of graves' orbitopathy

Investigative Ophthalmology and Visual Science

Volumn 53, Issue 9, 2012, Pages 5921-5929

  Yoon, Jin Sook ^a   Chae, Min Kyung ^a   Jang, Sun Young ^a   Lee, Sang Yeul ^a   Lee, Eun Jig ^a,b  

^a Yonsei University College of Medicine   (South Korea)

^b Brain Korea 21 Project for Medical Science   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN; FIBRONECTIN; GELATINASE A; GELATINASE B; INTERLEUKIN 1BETA; LACTATE DEHYDROGENASE; MATRILYSIN; QUERCETIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA; ACTA2 PROTEIN, HUMAN; ACTIN; ANTIOXIDANT; BIOLOGICAL MARKER; COLLAGEN TYPE 1; MATRIX METALLOPROTEINASE; MESSENGER RNA; TETRAZOLIUM; THIAZOLE DERIVATIVE; THIAZOLYL BLUE;

ADULT; ARTICLE; CELL MIGRATION; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY TEST; ENDOCRINE OPHTHALMOPATHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; WOUND HEALING; ZYMOGRAPHY; ADIPOSE TISSUE; CELL CULTURE; DOSE RESPONSE; DRUG EFFECT; FIBROSIS; GENETICS; METABOLISM; MIDDLE AGED; ORBIT; ORBIT DISEASE; PATHOLOGY;

ACTINS; ADIPOSE TISSUE; ADULT; ANTIOXIDANTS; BIOLOGICAL MARKERS; BLOTTING, WESTERN; CELLS, CULTURED; COLLAGEN TYPE I; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLASTS; FIBRONECTINS; FIBROSIS; GRAVES OPHTHALMOPATHY; HUMANS; L-LACTATE DEHYDROGENASE; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; ORBIT; ORBITAL DISEASES; QUERCETIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TETRAZOLIUM SALTS; THIAZOLES; WOUND HEALING;

EID: 84871709151     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.12-9646     Document Type: Article

References (44)

1. Garrity JA, Bahn RS. Pathogenesis of graves ophthalmopathy: implications for prediction, prevention, and treatment. Am J Ophthalmol. 2006;142:147-153.
2. Kuriyan AE, Phipps RP, Feldon SE. The eye and thyroid disease. Curr Opin Ophthalmol. 2008;19:499-506.
3. Bahn RS. Graves' ophthalmopathy. N Engl J Med. 2010;362:726-738.
4. Lehmann GM, Feldon SE, Smith TJ, Phipps RP. Immune mechanisms in thyroid eye disease. Thyroid. 2008;18:959-965.
5. Madhavan HN, Rao SB, Vijaya L, Neelakantan A. In vitro sensitivity of human Tenon's capsule fibroblasts to mitomycin C and its correlation with outcome of glaucoma filtration surgery. Ophthalmic Surg. 1995;26:61-67.
6. Prabhakar BS, Bahn RS, Smith TJ. Current perspective on the pathogenesis of Graves' disease and ophthalmopathy. Endocr Rev. 2003;24:802-835.
7. Chen CZ, Raghunath M. Focus on collagen: in vitro systems to study fibrogenesis and antifibrosis-state of the art. Fibrogenesis Tissue Repair. 2009;2:7.
8. Naik V, Khadavi N, Naik MN, et al. Biologic therapeutics in thyroid-associated ophthalmopathy: translating disease mechanism into therapy. Thyroid. 2008;18:967-971.
9. Zhao SX, Tsui S, Cheung A, Douglas RS, Smith TJ, Banga JP. Orbital fibrosis in a mouse model of Graves' disease induced by genetic immunization of thyrotropin receptor cDNA. J Endocrinol. 2011;210:369-377.
10. Hemmann S, Graf J, Roderfeld M, Roeb E. Expression of MMPs and TIMPs in liver fibrosis-a systematic review with special emphasis on anti-fibrotic strategies. J Hepatol. 2007;46:955-975.
11. Iredale JP. Tissue inhibitors of metalloproteinases in liver fibrosis. Int J Biochem Cell Biol. 1997;29:43-54.
12. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res. 2003;92:827-839.
13. Nagase H. Activation mechanisms of matrix metalloproteinases. Biol Chem. 1997;378:151-160.
14. Devipriya N, Sudheer AR, Srinivasan M, Menon VP. Effect of ellagic acid, a plant polyphenol, on fibrotic markers (MMPs and TIMPs) during alcohol-induced hepatotoxicity. Toxicol Mech Methods. 2007;17:349-356.
15. Han R, Smith TJ. Induction by IL-1 beta of tissue inhibitor of metalloproteinase-1 in human orbital fibroblasts: modulation of gene promoter activity by IL-4 and IFN-gamma. J Immunol. 2005;174:3072-3079.
16. Kim H, Choi YH, Park SJ, et al. Antifibrotic effect of Pirfenidone on orbital fibroblasts of patients with thyroid-associated ophthalmopathy by decreasing TIMP-1 and collagen levels. Invest Ophthalmol Vis Sci. 2010;51:3061-3066.
17. Mysliwiec J, Adamczyk M, Pawlowski P, Nikolajuk A, Gorska M. Serum gelatinases (MMP-2 and MMP-9) and VCAM-1 as a guideline in a therapeutic approach in Graves' ophthalmopathy. Endokrynol Pol. 2007;58:105-109.
18. Bartalena L, Pinchera A, Marcocci C. Management of Graves' ophthalmopathy: reality and perspectives. Endocr Rev. 2000;21: 168-199.
19. Yoon JS, Lee HJ, Choi SH, Chang EJ, Lee SY, Lee EJ. Quercetin inhibits IL-1beta-induced inflammation, hyaluronan production and adipogenesis in orbital fibroblasts from Graves' orbitopathy. PLoS One. 2011;6:e26261.
20. Comalada M, Camuesco D, Sierra S, et al. In vivo quercitrin antiinflammatory effect involves release of quercetin, which inhibits inflammation through down-regulation of the NF-kappaB pathway. Eur J Immunol. 2005;35:584-592.
21. Ying B, Yang T, Song X, et al. Quercetin inhibits IL-1 betainduced ICAM-1 expression in pulmonary epithelial cell line A549 through the MAPK pathways. Mol Biol Rep. 2009;36: 1825-1832.
22. Vasquez-Garzon VR, Arellanes-Robledo J, Garcia-Roman R, Aparicio-Rautista DI, Villa-Trevino S. Inhibition of reactive oxygen species and pre-neoplastic lesions by quercetin through an antioxidant defensemechanism. FreeRadicRes. 2009;43:128-137.
23. Rotelli AE, Aguilar CF, Pelzer LE. Structural basis of the antiinflammatory activity of quercetin: inhibition of the 5-hydroxytryptamine type 2 receptor. Eur Biophys J. 2009;38:865-871.
24. Rogerio AP, Dora CL, Andrade EL, et al. Anti-inflammatory effect of quercetin-loaded microemulsion in the airways allergic inflammatory model in mice. Pharmacol Res. 2010;61:288-297.
25. Baowen Q, Yulin Z, Xin W, et al. A further investigation concerning correlation between anti-fibrotic effect of liposomal quercetin and inflammatory cytokines in pulmonary fibrosis. Eur J Pharmacol. 2010;642:134-139.
26. Lee ES, Lee HE, Shin JY, Yoon S, Moon JO. The flavonoid quercetin inhibits dimethylnitrosamine-induced liver damage in rats. J Pharm Pharmacol. 2003;55:1169-1174.
27. Hu Q, Noor M, Wong YF, et al. In vitro anti-fibrotic activities of herbal compounds and herbs. Nephrol Dial Transplant. 2009; 24:3033-3041.
28. Nakamura T, Matsushima M, Hayashi Y, et al. Attenuation of transforming growth factor-beta-stimulated collagen production in fibroblasts by quercetin-induced heme oxygenase-1. Am J Respir Cell Mol Biol. 2011;44:614-620.
29. van Steensel L, van Hagen PM, Paridaens D, et al. Whole orbital tissue culture identifies imatinib mesylate and adalimumab as potential therapeutics for Graves' ophthalmopathy. Br J Ophthalmol. 2011;95:735-738.
30. Ambili M, Pillai MR, Sudhakaran PR. Characteristics of a 60K gelatinase involved in rat mammary gland involution. Indian J Biochem Biophys. 1997;34:347-353.
31. Yoon JS, Chae MK, Lee SY, Lee EJ. Anti-inflammatory effect of quercetin in a whole orbital tissue culture of Graves' orbitopathy. Br J Ophthalmol. 2012;96:1117-1121.
32. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T) Method. Methods. 2001;25:402-408.
33. Stahnke T, Lobler M, Kastner C, et al. Different fibroblast subpopulations of the eye: a therapeutic target to prevent postoperative fibrosis in glaucoma therapy. Exp Eye Res. 2012; 100:88-97.
34. Darby I, Skalli O, Gabbiani G. Alpha-smooth muscle actin is transiently expressed by myofibroblasts during experimental wound healing. Lab Invest. 1990;63:21-29.
35. Koumas L, Smith TJ, Feldon S, Blumberg N, Phipps RP. Thy-1 expression in human fibroblast subsets defines myofibroblastic or lipofibroblastic phenotypes. Am J Pathol. 2003;163:1291-1300.
36. Schuppan D, Ruehl M, Somasundaram R, Hahn EG. Matrix as a modulator of hepatic fibrogenesis. Semin Liver Dis. 2001;21: 351-372.
37. Takahara T, Furui K, Funaki J, et al. Increased expression of matrix metalloproteinase-II in experimental liver fibrosis in rats. Hepatology. 1995;21:787-795.
38. McLaughlin B, Cawston T, Weiss JB. Activation of the matrix metalloproteinase inhibitor complex by a low molecular weight angiogenic factor. Biochim Biophys Acta. 1991;1073:295-298.
39. Cunliffe IA, Richardson PS, Rees RC, Rennie IG. Effect of TNF, IL-1, and IL-6 on the proliferation of human Tenon's capsule fibroblasts in tissue culture. Br J Ophthalmol. 1995;79:590-595.
40. Lisi S, Botta R, Lemmi M, et al. Quercetin decreases proliferation of orbital fibroblasts and their release of hyaluronic acid. J Endocrinol Invest. 2011;34:521-527.
41. Manach C, Morand C, Crespy V, et al. Quercetin is recovered in human plasma as conjugated derivatives which retain antioxidant properties. FEBS Lett. 1998;426:331-336.
42. Moon JH, Tsushida T, Nakahara K, Terao J. Identification of quercetin 3-O-beta-D-glucuronide as an antioxidative metabolite in rat plasma after oral administration of quercetin. Free Radic Biol Med. 2001;30:1274-1285.
43. Yuan ZP, Chen LJ, Fan LY, et al. Liposomal quercetin efficiently suppresses growth of solid tumors in murine models. Clin Cancer Res. 2006;12:3193-3199.
44. Peres W, Tunon MJ, Collado PS, Herrmann S, Marroni N, Gonzalez-Gallego J. The flavonoid quercetin ameliorates liver damage in rats with biliary obstruction. J Hepatol. 2000;33:742-750.